Top of Mind

Perspective on neuroscience from the only global pharmaceutical company fully focused on the brain.

Date Features
August 1, 2018 CNN recently featured Doug Williamson, Chief Medical Officer and Vice President U.S. Medical, in an article on groundbreaking new approaches to Alzheimer’s treatments. The piece highlighted Lundbeck’s work with partner ImmunoBrain Checkpoint developing an immunotherapy for Alzheimer’s patients. Read more.
July 24, 2018 When it comes to new treatments for Alzheimer’s disease, no one has a clearer idea of what’s needed than Alzheimer’s patients and caregivers. But to date, their perspective has largely been absent from the drug development and approval process. Now, Lundbeck is working to change that. Lundbeck’s Chief Medical Officer, Dr. Doug Williamson, discusses a new initiative to raise the patient voice in Alzheimer’s research. Read more.
July 23, 2018 There’s a revolution underway in the Alzheimer’s research world. At the heart is a change in the way researchers and regulators define and stage the disease, and it might just lead to the breakthrough Alzheimer’s researchers, patients and families have been waiting for. Gary Tong, MD, PhD, Lundbeck’s US Therapeutic Area Head, Dementia, explains what’s changing and what it means. Read more.
June 15, 2018 As a leader of a company dedicated to helping people living with psychiatric disorders, Lundbeck's Peter Anastasiou is passionate about the need to fight stigma and raise awareness about suicide prevention. In this opinion piece, Peter shares what Lundbeck is doing to combat suicide. Read more.
May 8, 2018 For the third consecutive year, U.S. patient groups ranked Lundbeck first in corporate reputation. According to the new PatientView Corporate Reputation of Pharma, US Edition, Lundbeck also received top ranking in 10 individual reputational categories, including patient-centered strategy and acting with integrity. Read more.
April 26, 2018 Advances in Alzheimer’s research are occurring faster and with greater frequency than ever before. In an opinion piece published in Morning Consult, Dr. Gary Tong, Lundbeck's U.S. Therapeutic Area Head for Dementia, discusses this new era of Alzheimer’s research and the promise of potential new treatments. Read more.
April 6, 2018 The new global PatientView Corporate Reputation of Pharma survey results are out, and Lundbeck received the highest net promoter score (NPS) of all companies included. Peter Anastasiou, Executive Vice President and Head of North America, writes about why this measure matters and he shares how Lundbeck builds its reputation one relationship at a time. Read more.
March 7, 2018 The Lundbeck Foundation’s Brain Prize is the world’s largest brain research prize, and this year it was awarded to four pioneers in the battle against Alzheimer’s. Doug Williamson, MD, Chief Medical Officer & VP US Drug Development, shares how at Lundbeck we are building on the breakthroughs of the Brain Prize winners and attacking Alzheimer’s disease from a variety of angles. Read more.
November 20, 2017

This Epilepsy Awareness Month, Amy Solt-Magro, Lundbeck’s Vice President of Neurology Marketing, reflects on all she has learned working with the epilepsy community. And she shares how listening to their needs has changed how Lundbeck approaches all the patient communities we support. Read more.

October 9, 2017 Women in the workforce face many barriers to success, including the often-overlooked hurdle of depression. Research shows that 83 percent of women find depression to be a top barrier to workplace success. “This is one barrier to women’s success that we can – and should – take on,” writes Sally Benjamin Young, Lundbeck’s Vice President of Public Affairs. Read more.
September 28, 2017 Peter Anastasiou, President, Lundbeck North America addressed the link between mental health and the opioid crisis in a recent article. In it, he highlights the policies he believes are essential to addressing the problems of untreated mental illness and widespread opioid addiction. Read more.
July 19, 2017 For the second consecutive year, patient groups ranked Lundbeck first in corporate reputation among leading U.S. pharmaceutical companies. How has Lundbeck made such an impression with patients? “We’ve made patient advocacy part of everyone’s job,” writes Peter Anastasiou, Lundbeck’s Executive Vice President and Head of North America. Read more. 
March 29, 2017 Lundbeck is meeting with companies and organizations in Boston that could offer exciting possibilities for improving treatment of psychiatric and neurological disorders. Doug Williamson, Chief Medical Officer and VP of US Drug Development at Lundbeck talks about the importance of potential partnerships. Read more.  
March 13, 2017 Each year, the Lundbeck Foundation awards €1M (a sum greater than the Nobel Prize) to pioneers in brain research: the Brain Prize. Staffan Schuberg, Chief Commercial Officer & Executive Vice President at Lundbeck, congratulates this year’s winners. Read more.
March 13, 2017 On March 10, President Trump named Dr. Scott Gottlieb as his nominee to be the next commissioner of the U.S. Food & Drug Administration (FDA). Peter Anastasiou, President, Lundbeck North America, describes his hopes for the new commissioner’s agenda. Read more.
February 14, 2017 More parties are needed to join the fight for depression research. Dr. Doug Williamson, Chief Medical Officer & Vice President for Lundbeck U.S. Drug Development, shares his thoughts in a Care For your Mind Blog Post. Read more.
December 1, 2016 As part of Lundbeck’s continued commitment to the epilepsy community, we will present 16 posters in a scientific exhibit at the 2016 American Epilepsy Society (AES) Meeting. This infographic shares some of the highlights, including when and where the posters will be displayed at AES. Read more.
September 20, 2016 As a former D1 college football player, John Arena, Lundbeck’s Vice President and General Manager of US Psychiatry, understands toughness. When Ohio State head football coach Urban Meyer revealed that he struggles with anxiety, John was inspired by the coach’s decision to share his story. It’s important people like Urban – a “tough-guy” football coach – come forward to help reduce stigma, John writes. Read more.  
September 13, 2016 It is no secret that Parkinson's disease has a devastating effect on the people who are afflicted by it. Lundbeck's Vice President and General Manager of Neurology Lorena Di Carlo shares three reasons she has hope for Parkinson's disease as she gets ready to attend the 4th triennial World Parkinson Congress in Portland. Read more.
September 8, 2016 Despite afflicting more than 5 million U.S. patients – with a sharply expanding number of new diagnoses each year – Alzheimer’s disease remains a mystery to many Americans. In order to spread the word about Alzheimer's disease and build awareness of the devastation it exacts each day, we have created a guide to Alzheimer's fundamentals, from A to Z! Read more.
August 8, 2016 For the first time in more than a decade, the U.S. saw an uptick in mortality in 2015. Lundbeck's Executive Vice President & Global Chief Commercial Officer Staffan Schuberg shares his thoughts on this tragic development, the roots behind it, and where we must go from here. Read more.
July 28, 2016 Lundbeck North America President Peter Anastasiou offered some thoughts on the much needed recent bipartisan progress made to reform our mental health care system. Read more.
June 16, 2016 Dr. Gary Tong, Lundbeck's U.S. Therapeutic Area Head for Dementia, identifies five key challenges to achieving a breakthrough in Alzheimer's disease. Read more.
April 26, 2016 Groups like the World Health Organization and World Bank are currently coming together to address global unmet need in mental healthcare. Lundbeck's Global Chief Commercial Officer Staffan Schuberg offers perspective on the importance of this type of partnership and the urgency of this work. Read more
April 15, 2016 Lundbeck's North America President Peter Anastasiou reflects on the importance of reputation in the pharmaceutical industry. Read more
March 1, 2016 ESPN's Mike Greenberg offered a powerful plea for people to better understand depression for the complicated and devastating disease that it is. Lundbeck's North America President Peter Anastasiou offered his thoughts on the importance of changing the conversation about depression. Read more.
February 29, 2016 Depression is a complicated disease with huge unmet need. Lundbeck's Global Chief Commercial Officer Staffan Schuberg reflects on the progress left to be made. Read more.
February 9, 2016 Dr. Gary Tong, Lundbeck's U.S. Therapeutic Area Head for Dementia, offers perspective on exciting parallels between progress in Alzheimer's research and the "Cancer Moonshot." Read more
November 19, 2015 Lundbeck's Global Chief Commercial Officer Staffan Schuberg offers his thoughts on the current momentum behind addressing the unmet need in mental health. Read more.
September 10, 2015 Lundbeck's Global Chief Commercial Officer Staffan Schuberg offers three necessary principles in the effort to defeat Alzheimer's disease. Read more
July 17, 2015 People often underestimate the complexity of depression and the various ways it impacts patients' lives. Lundbeck's Global Chief Commercial Officer Staffan Schuberg encourages prominent dictionaries to bring their definition of depression in line with the realities of the disease. Read more.
May 13, 2015 Lundbeck's Global Chief Commercial Officer Staffan Schuberg's perspective on the global approach we must take to brain research. Read more
April 23, 2015 Lundbeck's Global Chief Commercial Officer Staffan Schuberg shares three insights on driving a patient-focused approach to business. Read more

 

Alzheimer's From A to Z

Every 65 seconds, someone in the U.S. develops Alzheimer’s disease. Yet it remains a mystery to many. To help raise Awareness of Alzheimer’s and the impact it has on tens of millions of people worldwide, here is a guide to Alzheimer’s fundamentals, from A to Z! Read more.

VIDEO

Lundbeck US Tops Corporate-Reputation Rankings for Third Consecutive Year

According to the new PatientView Corporate Reputation of Pharma, US Edition, Lundbeck also received top ranking in 10 individual reputational categories, including patient-centered strategy and acting with integrity.

Read More

Brain Research, By The Numbers

The burden of brain disorders is immense and rising. According to the World Health Organization, 700 million people around the world are affected by neurologic and psychiatric diseases. Medicines that treat brain disorders take longer and cost more to develop than other drugs. But the cost of not investing in brain research is too great. Read more.

Five Key Challenges to Achieving a Breakthrough in Alzheimer’s Disease

Dr. Gary Tong, U.S. Therapeutic Area Head of Dementia at Lundbeck identifies five key challenges to achieving a breakthrough in Alzheimer's disease.

Read more.

VIDEO

Studio E: The Epilepsy Art Therapy Program

Caring for people with brain disorders goes far beyond medication.

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.